Long-term Clinical Outcome of Intensity-modulated Radiation Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Overview
Authors
Affiliations
Purpose: This study evaluated the effectiveness and safety of intensity-modulated radiation therapy (IMRT) for locally advanced esophageal squamous cell carcinoma (ESCC).
Methods: Between August 2009 and December 2011, 112 patients with pathologically confirmed ESCC treated with IMRT at Jiangsu Province People's Hospital and Nantong Tumor Hospital were included in a retrospective analysis. Patients received either IMRT alone (group A) or concurrent chemoradiotherapy (CRT) (group B). A radiation dose of 60-66 Gy administered in 30-33 fractions was delivered to the tumor. The patients in group B simultaneously received 2 cycles of cisplatin-based doublets with either 5-fluorouracil or taxotere. The Kaplan-Meier method was used to compute the survival time. Early and late toxicities were scored according to CTCAE v.3.0.
Results: The response rate of group B (91.07%) was not significantly greater than that of group A (89.29%) (χ2 = 0.10, p = 0.75). The 1- and 3-year survival rates of group B (87.5% and 57.14%, respectively) were greater than those of group A (69.64% and 37.50%, respectively). The difference in overall survival was statistically significant between groups A and B (χ2 = 5.30, p = 0.02; χ2 = 4.33, p = 0.04). Hematological toxicity, gastrointestinal toxicity, and treatment-related esophagitis were significantly higher in group B than group A (16.07% vs. 33.93%, p = 0.04; 10.71% vs. 26.79%, p = 0.03; 19.64% vs. 44.64%, p = 0.01). However, intergroup differences in terms of late toxicity were not significant.
Conclusions: IMRT was a practical and feasible technique to treat ESCC. Concurrent CRT could increase local tumor control and long-term survival. The CRT regimen was associated with a higher incidence of acute gastrointestinal and hematological toxicity.
Liou Y, Lan T, Lan C Cancers (Basel). 2024; 16(3).
PMID: 38339409 PMC: 10854668. DOI: 10.3390/cancers16030658.
Zeng C, Zhai T, Chen J, Guo L, Huang B, Guo H Radiat Oncol. 2021; 16(1):8.
PMID: 33436018 PMC: 7805131. DOI: 10.1186/s13014-020-01699-w.
Bai X, Dang J, Chen Z, He Z, Li G J Oncol. 2020; 2020:6582341.
PMID: 32308681 PMC: 7142393. DOI: 10.1155/2020/6582341.
Liu S, Ren S, Ding W, Ge X, Cao Y, Zhang S Ann Transl Med. 2019; 7(14):331.
PMID: 31475201 PMC: 6694257. DOI: 10.21037/atm.2019.06.45.